Obsidian Therapeutics closed at $14.43 on Nov 2, down 2.43%, 20.3% below its highest close since Sep 11. Volume of 526.0K shares was 1.58× its 20-day average (above normal).
Split-adjusted performance: +6.2% over one month.
Short interest was 1.1M shares at the Oct 15 settlement, up 22.3% from the prior report (2.2% of float, 3.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| OBXObsidian Therapeutics | $14.43 | −2.43% | — | — | — | — | $891.4M | |
| LTGOLatigo Biotherapeutics | $13.51 | −3.15% | — | — | — | — | $895.7M | Compare |
| JBIOJade Biosciences | $13.93 | −0.92% | −43.2% | — | — | — | $885.9M | Compare |
| KURAKura Oncology | $9.79 | −4.58% | +5.8% | +36.5% | −327.3% | — | $870.9M | Compare |
| ANROAlto Neuroscience | $22.19 | −1.81% | −11.9% | — | — | — | $870.8M | Compare |
| ORICOric Pharmaceuticals | $9.07 | −1.84% | −5.8% | — | — | — | $940.1M | Compare |
| RIGLRigel Pharmaceuticals Inc. (New) | $50.53 | −1.52% | +71.1% | −22.6% | 22.0% | 2.9 | $943.9M | Compare |
| ALMSAlumis | $6.38 | −5.20% | −74.7% | −37.7% | −8557.2% | — | $825.8M | Compare |
| CYRXCryoPort | $16.23 | −6.13% | +59.0% | +7.7% | −20.9% | — | $822.0M | Compare |
No recent articles focused on Obsidian Therapeutics.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
